Biotech companies leading the way with exosome human clinical trials
A number of companies are in the preclinical phase of exosome therapy research.
In Korea, Ilias and ExoCoBio are developing exosome therapeutics. Ilias – founded by faculty from the Korean Advanced Institute of Science and Technology (KAIST) – specialises in loading large protein therapeutics into exosomes.
It is currently carrying out preclinical research toward treating sepsis, preterm labour and Gaucher’s disease. ExoCoBio is focusing on the native regenerative capacity of exosomes derived from mesenchymal stem cells, including to treat atopic dermatitis.